Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943031 | 0.92 | LMNA (0.46) | GLP1RCYP1A2CYP3A4TSHRMAPK1 | |
| SCHEMBL5598558 | 0.91 | PPARA (0.43) | GLP1RCYP1A2CYP3A4STING1PTGER4 | |
| SCHEMBL1940860 | 0.90 | BRD4 (0.45) | GLP1RCYP1A2CYP3A4TSHRMAPK1 | |
| SCHEMBL5598194 | 0.88 | PTGER4 (0.41) | GLP1RPTGER4EIF4EBP1 | |
| SCHEMBL1940913 | 0.86 | STING1 (0.40) | GLP1RCYP1A2CYP3A4TSHRMAPK1 | |
| SCHEMBL1941058 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP3A4TSHRMAPK1PTGER4 | |
| SCHEMBL1941549 | 0.81 | CYP1A2 (0.47) | CYP1A2CYP3A4TSHRMAPK1PTGER4 | |
| SCHEMBL14521393 | 0.81 | PTGER4 (0.39) | CYP1A2CYP3A4STING1PTGER4CYP2C19 | |
| SCHEMBL3960092 | 0.79 | PTGER4 (0.43) | PTGER4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14522391 | 0.78 | STING1 (0.42) | STING1PTGER4ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466166-B2 | Benzimidazole derivatives as selective acid pump inhibitors | RAQUALIA PHARMA INC. (JP) | 2013-06-18 | — | — | US | disclosed |
| EP-2081939-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS | RAQUALIA PHARMA INC (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20100048532-A1 | Benzimidazole Derivatives as Selective Acid Pump Inhibitors | RAQUALIA PHARMA INC. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2081939-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS | RaQualia Pharma Inc (JP) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008035195-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS | RAQUALIA PHARMA INC. (JP) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007072142-A2 | BENZIMIDAZOLE-5-CARBOXAMIDE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048532-A1 | Benzimidazole Derivatives as Selective Acid Pump Inhibitors | HRH2, HRH4, HRH1 | GLP1R 1430/4885CYP1A2 1807/4885CYP3A4 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.